Molecular biomarker development for anti-EGFR therapy: Moving beyond EGFR expression

Clinical Colorectal Cancer

Volumn 7, Issue 3, 2008, Pages 162-

  Chu, Edward ^a,b  

^a Section of Medical Oncology

^b YALE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHIREGULIN; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; EPIREGULIN; GROWTH FACTOR; IRINOTECAN; K RAS PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; MOLECULAR MARKER; PANITUMUMAB; RAF PROTEIN; RAS PROTEIN;

CLINICAL TRIAL; COLORECTAL CANCER; DISEASE FREE SURVIVAL; DNA SEQUENCE; DRUG APPROVAL; EDITORIAL; GENE MUTATION; HUMAN; IMMUNOHISTOCHEMISTRY; METASTASIS; ONCOGENE K RAS; PROTEIN EXPRESSION; TUMOR GENE; WILD TYPE;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; MUTATION; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TUMOR MARKERS, BIOLOGICAL;

EID: 44449120025     PISSN: 15330028     EISSN: None     Source Type: Journal    
DOI: 10.3816/CCC.2008.n.021     Document Type: Editorial

References (3)

1. Freeman DJ, Juan T, Reiner M, et al. Association of K-ras mutational status and clinical outcomes in patients with metastatic colorectal cancer receiving panitumumab alone. Clin Colorectal Cancer 2008; 7:184-90.
2. Amado RG, Wolf M, Freeman D, et al. Panitumumab (pmab) efficacy and patient-reported outcomes (PRO) in metastatic colorectal cancer (mCRC) patients (pts) with wild-type (WT) KRAS tumor status. Presented at: the 2008 Gastrointestinal Cancers Symposium; January 25-27, 2008; Orlando, FL. Abstract 278.
3. Tejpar S, De Roock W, Biesmans B, et al. High amphiregulin and epiregulin expression in KRAS wild type colorectal primaries predicts response and survival benefit after treatment with cetuximab and irinotecan for metastatic disease. Presented at: the 2008 Gastrointestinal Cancers Symposium; January 25-27, 2008; Orlando, FL. Abstract 411.